Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00563381
First received: November 22, 2007
Last updated: November 27, 2013
Last verified: July 2012
  Purpose

This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits.

The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations.

The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation.

The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator.

Only COPD exacerbations with onset during randomised treatment will be included in the analysis.


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: Tiotropium bromide
Drug: Salmeterol
Drug: Placebo Salmeterol
Drug: Placebo Tiotropium
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • First Occurrence of (Moderate or Severe) COPD Exacerbation [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).


Secondary Outcome Measures:
  • COPD Exacerbations Per Patient-year Leading to Hospitalisation [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • Number of Participants With at Least One COPD Exacerbation [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • COPD Exacerbations Per Patient-year [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • First Occurrence of COPD Exacerbation Leading to Hospitalization [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation leading to hospitalisation and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • Number of Participants With at Least One COPD Exacerbation Leading to Hospitalisation [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • Occurrence of Premature Discontinuation of Trial Medication [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Occurrence analysed by Cox regression as time to premature discontinuation of trial medication and reported as hazard ratio

  • Number of Participants With Premature Discontinuation of Trial Medication [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
  • First Occurrence of COPD Exacerbation or Discontinuation of Trial Medication Because of Worsening of Underlying Disease, Whichever Comes First [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation or discontinuation of trial medication because of worsening of underlying disease, whichever comes first and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • First Occurrence of COPD Exacerbations Treated With Systemic Steroids [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation treated with systemic steroids and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • First Occurrence of COPD Exacerbations Treated With Antibiotics [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation treated with antibiotics and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • First Occurrence of COPD Exacerbations Treated With Systemic Steroids and Antibiotics [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    First occurrence analysed by Cox regression as time to first exacerbation treated with systemic steroids and antibiotics and reported as hazard ratio. An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • COPD Exacerbations Treated With Systemic Steroids Per Patient-year [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • COPD Exacerbations Treated With Antibiotics Per Patient-year [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • COPD Exacerbations Treated With Systemic Steroids and Antibiotics Per Patient-year [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    An exacerbation was defined as an increase or new onset of more than 1 symptom (cough, sputum, wheezing, dyspnoea, chest tightness), with at least 1 symptom lasting at least 3 days and requiring treatment with systemic steroids and/or antibiotics (moderate exacerbation) or hospitalisation (severe exacerbation).

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 1 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 2 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 3 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 4 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 5 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 6 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 7 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 8 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 9 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 10 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 11 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 12 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 13 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 14 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 15 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute

  • Pre-dose Morning PEFR Measured by Patients at Home During the First Four Months of Randomised Treatment (Weekly Means Will be Calculated), Week 16 [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    PEFR means peak expiratory flow rate and is measured in liter per minute


Enrollment: 7376
Study Start Date: January 2008
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Tiotropium + Placebo
patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
Drug: Tiotropium bromide
18 mcg/daily
Drug: Placebo Salmeterol
Placebo identical to Salmeterol device
Active Comparator: Salmeterol + Placebo
patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
Drug: Salmeterol
100 mcg/daily
Drug: Placebo Tiotropium
Placebo identical to Tiotropium device

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and must meet the following criteria at Visit 1:

    Patients must have relatively stable, moderate to very severe airway obstruction with a post-bronchodilator FEV1 <=70% of predicted normal and FEV1 <=70% of FVC post-bronchodilator (i.e. 30 minutes after inhalation of 4 puffs of 100 µg salbutamol or equivalent SABA). Predicted normal values will be calculated according to ECSC.

    For Height measured in inches Males: FEV1 predicted (L) = 4.30 x (height (inches) / 39.37)-0.029 x age (yrs) - 2.49 Females:FEV1 predicted (L) = 3.95 x (height (inches) / 39.37)-0.025 x age (yrs) - 2.60 For Height measured in metres Males: FEV1 predicted (L) = 4.30 x (height (metres)) - 0.029 x age (years) - 2.49 Females: FEV1 predicted (L) = 3.95 x (height (metres)) - 0.025 x age (years) - 2.60

  2. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial.
  3. Male or female patients 40 years of age or older.
  4. Patients with a history of at least one exacerbation within the past year requiring treatment with either antibiotics and/or systemic steroids and/or hospitalisation.
  5. Patients must be current or ex-smokers with a smoking history of >= 10 pack-years. (Patients who have never smoked cigarettes must be excluded.)
  6. Patients must be able to perform all study-related procedures including technically acceptable pulmonary function tests (PFTs).
  7. Patients must be able to inhale medication in a competent manner from the HandiHaler and a metered dose inhaler (MDI).
  8. Patients must be able to maintain records (patient daily diary card) during the study period as required in the protocol.

Exclusion Criteria:

  1. Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients' ability to participate in the study.
  2. Patients with a diagnosis of asthma.
  3. Patients with a life-threatening pulmonary obstruction, or a history of cystic fibrosis.
  4. Patients with known active tuberculosis.
  5. Patients with a known symptomatic prostatic hyperplasia or bladder neck obstruction. Patients with symptomatically-controlled prostatic hyperplasia on medication may be included and should continue their medication.
  6. Patients with known narrow-angle glaucoma.
  7. Patients with a history of myocardial infarction within the year prior to Visit 1.
  8. Patients with a history of hospital admission for heart failure within the year prior to Visit 1.
  9. Patients with cardiac arrhythmia requiring medical or surgical treatment.
  10. Patients with severe cardiovascular disorders.
  11. Patients with a known hypersensitivity to anticholinergic drugs, beta-adrenergics, lactose or any other component of the medication delivery system.
  12. Patients with known moderate or severe renal insufficiency (known creatinine clearance of <= 50 mL/min).
  13. Patients with untreated known hypokalaemia.
  14. Patients with untreated known thyrotoxicosis.
  15. Patients with brittle/unstable diabetes mellitus.
  16. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion 1.
  17. Patients who have taken an investigational drug within 30 days or six half-lives (whichever is greater) prior to Screening Visit (Visit 1).
  18. Use of systemic corticosteroid medication at unstable doses (i.e less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone per day or 20 mg every other day.
  19. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g Norplant) for at least three months prior to, and for the duration of the trial.
  20. Previous participation (receipt of randomised treatment) in this study.
  21. Patients who are currently participating in another study.
  22. Patients with any respiratory infection or COPD exacerbation in the four weeks prior to the Screening Visit (Visit 1) or during the run-in period should be postponed. In the case of a respiratory infection or COPD exacerbation during the run-in period, the latter may be extended up to four weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563381

  Hide Study Locations
Locations
Austria
205.389.1020 Boehringer Ingelheim Investigational Site
Feldbach, Austria
205.389.1010 Boehringer Ingelheim Investigational Site
Feldkirch, Austria
205.389.1011 Boehringer Ingelheim Investigational Site
Grimmenstein/Hochegg, Austria
205.389.1003 Boehringer Ingelheim Investigational Site
Gänserndorf, Austria
205.389.1005 Boehringer Ingelheim Investigational Site
Hallein, Austria
205.389.1023 Boehringer Ingelheim Investigational Site
Linz, Austria
205.389.1001 Boehringer Ingelheim Investigational Site
Mittersill, Austria
205.389.1027 Boehringer Ingelheim Investigational Site
Salzburg, Austria
205.389.1026 Boehringer Ingelheim Investigational Site
Schlüßlberg, Austria
205.389.1016 Boehringer Ingelheim Investigational Site
Spittal/Drau, Austria
205.389.1022 Boehringer Ingelheim Investigational Site
Steyr, Austria
205.389.1021 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1018 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1006 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1014 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1002 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1029 Boehringer Ingelheim Investigational Site
Wien, Austria
205.389.1017 Boehringer Ingelheim Investigational Site
Zwettl, Austria
Belgium
205.389.1120 Boehringer Ingelheim Investigational Site
Buizingen, Belgium
205.389.1124 Boehringer Ingelheim Investigational Site
Cerexhe Heuseux, Belgium
205.389.1116 Boehringer Ingelheim Investigational Site
Chenée (Liége), Belgium
205.389.1121 Boehringer Ingelheim Investigational Site
Dour, Belgium
205.389.1113 Boehringer Ingelheim Investigational Site
Gembloux, Belgium
205.389.1117 Boehringer Ingelheim Investigational Site
Gozée, Belgium
205.389.1126 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
205.389.1129 Boehringer Ingelheim Investigational Site
Natoye, Belgium
205.389.1130 Boehringer Ingelheim Investigational Site
Quaregnon, Belgium
205.389.1115 Boehringer Ingelheim Investigational Site
Thuillies, Belgium
205.389.1107 Boehringer Ingelheim Investigational Site
Wetteren, Belgium
Bulgaria
205.389.3911 Boehringer Ingelheim Investigational Site
Pazardjik, Bulgaria
205.389.3915 Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
205.389.3903 Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
205.389.3918 Boehringer Ingelheim Investigational Site
Rousse, Bulgaria
205.389.3914 Boehringer Ingelheim Investigational Site
Sliven, Bulgaria
205.389.3902 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3906 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3907 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
205.389.3908 Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
205.389.3916 Boehringer Ingelheim Investigational Site
Troyan, Bulgaria
205.389.3912 Boehringer Ingelheim Investigational Site
Varna, Bulgaria
205.389.3901 Boehringer Ingelheim Investigational Site
Veliko Turnovo, Bulgaria
Czech Republic
205.389.1211 Boehringer Ingelheim Investigational Site
Benesov, Czech Republic
205.389.1213 Boehringer Ingelheim Investigational Site
Beroun, Czech Republic
205.389.1220 Boehringer Ingelheim Investigational Site
Beroun, Czech Republic
205.389.1204 Boehringer Ingelheim Investigational Site
Brno-Kralovo Pole, Czech Republic
205.389.1212 Boehringer Ingelheim Investigational Site
Cheb, Czech Republic
205.389.1205 Boehringer Ingelheim Investigational Site
Havlickuv Brod, Czech Republic
205.389.1230 Boehringer Ingelheim Investigational Site
Humpolec, Czech Republic
205.389.1208 Boehringer Ingelheim Investigational Site
Jaromer, Czech Republic
205.389.1219 Boehringer Ingelheim Investigational Site
Kyjov, Czech Republic
205.389.1225 Boehringer Ingelheim Investigational Site
Liberec, Czech Republic
205.389.1218 Boehringer Ingelheim Investigational Site
Litomerice, Czech Republic
205.389.1214 Boehringer Ingelheim Investigational Site
Lovosice, Czech Republic
205.389.1207 Boehringer Ingelheim Investigational Site
Neratovice, Czech Republic
205.389.1222 Boehringer Ingelheim Investigational Site
Ostrava, Czech Republic
205.389.1209 Boehringer Ingelheim Investigational Site
Plzen, Czech Republic
205.389.1216 Boehringer Ingelheim Investigational Site
Plzen, Czech Republic
205.389.1217 Boehringer Ingelheim Investigational Site
Praha 13, Czech Republic
205.389.1215 Boehringer Ingelheim Investigational Site
Praha 17, Czech Republic
205.389.1232 Boehringer Ingelheim Investigational Site
Praha 3, Czech Republic
205.389.1229 Boehringer Ingelheim Investigational Site
Praha 4, Czech Republic
205.389.1223 Boehringer Ingelheim Investigational Site
Praha 5, Czech Republic
205.389.1227 Boehringer Ingelheim Investigational Site
Praha 5, Czech Republic
205.389.1224 Boehringer Ingelheim Investigational Site
Praha 6 - Brevnov, Czech Republic
205.389.1228 Boehringer Ingelheim Investigational Site
Prerov, Czech Republic
205.389.1231 Boehringer Ingelheim Investigational Site
Rokycany, Czech Republic
205.389.1221 Boehringer Ingelheim Investigational Site
Strakonice, Czech Republic
205.389.1206 Boehringer Ingelheim Investigational Site
Tremosna, Czech Republic
205.389.1201 Boehringer Ingelheim Investigational Site
Zatec, Czech Republic
205.389.1210 Boehringer Ingelheim Investigational Site
Znojmo, Czech Republic
Denmark
205.389.1304 Boehringer Ingelheim Investigational Site
Copenhagen, Denmark
205.389.1309 Boehringer Ingelheim Investigational Site
Frederikssund, Denmark
205.389.1301 Boehringer Ingelheim Investigational Site
Helsingor, Denmark
205.389.1308 Boehringer Ingelheim Investigational Site
Helsingør, Denmark
205.389.1311 Boehringer Ingelheim Investigational Site
Holstebro, Denmark
205.389.1302 Boehringer Ingelheim Investigational Site
Næstved, Denmark
205.389.1303 Boehringer Ingelheim Investigational Site
Roskilde, Denmark
205.389.1310 Boehringer Ingelheim Investigational Site
Skive, Denmark
205.389.1312 Boehringer Ingelheim Investigational Site
Sonderborg, Denmark
205.389.1307 Boehringer Ingelheim Investigational Site
Værløse, Denmark
Finland
205.389.1402 Boehringer Ingelheim Investigational Site
Helsinki, Finland
205.389.1416 Boehringer Ingelheim Investigational Site
Hyvinkää, Finland
205.389.1410 Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
205.389.1404 Boehringer Ingelheim Investigational Site
Lahti, Finland
205.389.1417 Boehringer Ingelheim Investigational Site
Lappeenranta, Finland
205.389.1415 Boehringer Ingelheim Investigational Site
Lohja, Finland
205.389.1411 Boehringer Ingelheim Investigational Site
Mikkeli, Finland
205.389.1409 Boehringer Ingelheim Investigational Site
Pori, Finland
205.389.1412 Boehringer Ingelheim Investigational Site
Preitilä Paimio, Finland
205.389.1407 Boehringer Ingelheim Investigational Site
Turku, Finland
France
205.389.1607 Boehringer Ingelheim Investigational Site
Bauge, France
205.389.1525 Boehringer Ingelheim Investigational Site
Beauvais, France
205.389.1523 Boehringer Ingelheim Investigational Site
Bethune, France
205.389.1571 Boehringer Ingelheim Investigational Site
Cestas, France
205.389.1561 Boehringer Ingelheim Investigational Site
Charry le Rouet, France
205.389.1507 Boehringer Ingelheim Investigational Site
Cholet, France
205.389.1606 Boehringer Ingelheim Investigational Site
Ecouflant, France
205.389.1554 Boehringer Ingelheim Investigational Site
Ermont, France
205.389.1597 Boehringer Ingelheim Investigational Site
La Barre de Monts, France
205.389.1581 Boehringer Ingelheim Investigational Site
La Jubaudière, France
205.389.1598 Boehringer Ingelheim Investigational Site
La Roche sur Yon, France
205.389.1536 Boehringer Ingelheim Investigational Site
La Roche Sur Yon, France
205.389.1501 Boehringer Ingelheim Investigational Site
Le Kremlin Bicetre, France
205.389.1503 Boehringer Ingelheim Investigational Site
Le Mans Cedex, France
205.389.1586 Boehringer Ingelheim Investigational Site
Le Pradet, France
205.389.1564 Boehringer Ingelheim Investigational Site
Marseille, France
205.389.1565 Boehringer Ingelheim Investigational Site
Marseille, France
205.389.1558 Boehringer Ingelheim Investigational Site
Marseille, France
205.389.1530 Boehringer Ingelheim Investigational Site
Marseille, France
205.389.1528 Boehringer Ingelheim Investigational Site
Marseille, France
205.389.1539 Boehringer Ingelheim Investigational Site
Montfermeil, France
205.389.1608 Boehringer Ingelheim Investigational Site
Nantes, France
205.389.1526 Boehringer Ingelheim Investigational Site
Nice, France
205.389.1504 Boehringer Ingelheim Investigational Site
Nimes, France
205.389.1502 Boehringer Ingelheim Investigational Site
Ollioules, France
205.389.1541 Boehringer Ingelheim Investigational Site
Orleans, France
205.389.1527 Boehringer Ingelheim Investigational Site
Perpignan, France
205.389.1532 Boehringer Ingelheim Investigational Site
PIERRE BENITE cédex, France
205.389.1553 Boehringer Ingelheim Investigational Site
Rennes cedex 9, France
205.389.1555 Boehringer Ingelheim Investigational Site
Saint Dié des Vosges, France
205.389.1575 Boehringer Ingelheim Investigational Site
Saint Germain du Puch, France
205.389.1572 Boehringer Ingelheim Investigational Site
Saint Laurent, France
205.389.1547 Boehringer Ingelheim Investigational Site
Saint Laurent du Var, France
205.389.1567 Boehringer Ingelheim Investigational Site
Saint Orens de Cameville, France
205.389.1577 Boehringer Ingelheim Investigational Site
Saint Pierre Montlimard, France
205.389.1531 Boehringer Ingelheim Investigational Site
Saint Quentin, France
205.389.1569 Boehringer Ingelheim Investigational Site
Seysses, France
205.389.1514 Boehringer Ingelheim Investigational Site
St-Etienne, France
205.389.1510 Boehringer Ingelheim Investigational Site
Strasbourg, France
205.389.1522 Boehringer Ingelheim Investigational Site
Strasbourg, France
205.389.1520 Boehringer Ingelheim Investigational Site
Sélestat, France
205.389.1588 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1589 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1590 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1519 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1515 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1595 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1512 Boehringer Ingelheim Investigational Site
Toulon, France
205.389.1542 Boehringer Ingelheim Investigational Site
Toulouse, France
205.389.1574 Boehringer Ingelheim Investigational Site
Villenave D'ornon, France
Germany
205.389.1741 Boehringer Ingelheim Investigational Site
Aachen, Germany
205.389.1857 Boehringer Ingelheim Investigational Site
Aalen, Germany
205.389.1934 Boehringer Ingelheim Investigational Site
Auerbach, Germany
205.389.1868 Boehringer Ingelheim Investigational Site
Augsburg, Germany
205.389.1887 Boehringer Ingelheim Investigational Site
Augsburg, Germany
205.389.1707 Boehringer Ingelheim Investigational Site
Bad Lippspringe, Germany
205.389.1722 Boehringer Ingelheim Investigational Site
Bad Pymont, Germany
205.389.1850 Boehringer Ingelheim Investigational Site
Bad Wörishofen, Germany
205.389.1765 Boehringer Ingelheim Investigational Site
Bahrdorf, Germany
205.389.1792 Boehringer Ingelheim Investigational Site
Beckum, Germany
205.389.1801 Boehringer Ingelheim Investigational Site
Bensheim, Germany
205.389.1946 Boehringer Ingelheim Investigational Site
Bensheim, Germany
205.389.1824 Boehringer Ingelheim Investigational Site
Bergisch Gladbach, Germany
205.389.1709 Boehringer Ingelheim Investigational Site
Bergkamen, Germany
205.389.1750 Boehringer Ingelheim Investigational Site
Berkatal-Frankershausen, Germany
205.389.1981 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1960 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1701 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1847 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1931 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1937 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1983 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1969 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1743 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1984 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1932 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1867 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1903 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1855 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1861 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1789 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1790 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1769 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1862 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.389.1747 Boehringer Ingelheim Investigational Site
Bocholt, Germany
205.389.1808 Boehringer Ingelheim Investigational Site
Bochum, Germany
205.389.1811 Boehringer Ingelheim Investigational Site
Bochum, Germany
205.389.1828 Boehringer Ingelheim Investigational Site
Bonn, Germany
205.389.1870 Boehringer Ingelheim Investigational Site
Bonn, Germany
205.389.1705 Boehringer Ingelheim Investigational Site
Borna, Germany
205.389.1809 Boehringer Ingelheim Investigational Site
Brandenburg/Havel, Germany
205.389.1859 Boehringer Ingelheim Investigational Site
Bruchsal, Germany
205.389.1734 Boehringer Ingelheim Investigational Site
Camburg, Germany
205.389.1923 Boehringer Ingelheim Investigational Site
Celle, Germany
205.389.1901 Boehringer Ingelheim Investigational Site
Coswig, Germany
205.389.1891 Boehringer Ingelheim Investigational Site
Cottbus, Germany
205.389.1858 Boehringer Ingelheim Investigational Site
Deggendorf, Germany
205.389.1784 Boehringer Ingelheim Investigational Site
Donaueschingen, Germany
205.389.1713 Boehringer Ingelheim Investigational Site
Dortmund, Germany
205.389.1706 Boehringer Ingelheim Investigational Site
Dresden, Germany
205.389.1967 Boehringer Ingelheim Investigational Site
Düren, Germany
205.389.1814 Boehringer Ingelheim Investigational Site
Engelskirchen, Germany
205.389.1773 Boehringer Ingelheim Investigational Site
Ense, Germany
205.389.1727 Boehringer Ingelheim Investigational Site
Eppelborn-Bubach, Germany
205.389.1864 Boehringer Ingelheim Investigational Site
Erfurt, Germany
205.389.1940 Boehringer Ingelheim Investigational Site
Erlangen, Germany
205.389.1900 Boehringer Ingelheim Investigational Site
Eschwege, Germany
205.389.1982 Boehringer Ingelheim Investigational Site
Essen, Germany
205.389.1975 Boehringer Ingelheim Investigational Site
Essen, Germany
205.389.1758 Boehringer Ingelheim Investigational Site
Essen, Germany
205.389.1724 Boehringer Ingelheim Investigational Site
Ettlingen, Germany
205.389.1806 Boehringer Ingelheim Investigational Site
Feldkirchen-Westerham, Germany
205.389.1976 Boehringer Ingelheim Investigational Site
Forchheim, Germany
205.389.1795 Boehringer Ingelheim Investigational Site
Frankenberg, Germany
205.389.1905 Boehringer Ingelheim Investigational Site
Frankfurt/Main, Germany
205.389.1752 Boehringer Ingelheim Investigational Site
Fuldatal-Ihringshausen, Germany
205.389.1943 Boehringer Ingelheim Investigational Site
Föhren, Germany
205.389.1971 Boehringer Ingelheim Investigational Site
Fürth, Germany
205.389.1766 Boehringer Ingelheim Investigational Site
Gars, Germany
205.389.1977 Boehringer Ingelheim Investigational Site
Gelsenkirchen, Germany
205.389.1744 Boehringer Ingelheim Investigational Site
Georgensgmünd, Germany
205.389.1875 Boehringer Ingelheim Investigational Site
Gießen, Germany
205.389.1836 Boehringer Ingelheim Investigational Site
Gifhorn, Germany
205.389.1914 Boehringer Ingelheim Investigational Site
Goch, Germany
205.389.1886 Boehringer Ingelheim Investigational Site
Greiz, Germany
205.389.1768 Boehringer Ingelheim Investigational Site
Grünberg, Germany
205.389.1751 Boehringer Ingelheim Investigational Site
Göttingen, Germany
205.389.1831 Boehringer Ingelheim Investigational Site
Hagen, Germany
205.389.1827 Boehringer Ingelheim Investigational Site
Halle, Germany
205.389.1980 Boehringer Ingelheim Investigational Site
Hamburg, Germany
205.389.1924 Boehringer Ingelheim Investigational Site
Hamburg, Germany
205.389.1917 Boehringer Ingelheim Investigational Site
Hamburg, Germany
205.389.1925 Boehringer Ingelheim Investigational Site
Hamburg, Germany
205.389.1716 Boehringer Ingelheim Investigational Site
Hammah, Germany
205.389.1702 Boehringer Ingelheim Investigational Site
Hammelburg, Germany
205.389.1802 Boehringer Ingelheim Investigational Site
Hannover, Germany
205.389.1712 Boehringer Ingelheim Investigational Site
Harsewinkel, Germany
205.389.1738 Boehringer Ingelheim Investigational Site
Hauzenberg, Germany
205.389.1860 Boehringer Ingelheim Investigational Site
Hemmingen, Germany
205.389.1949 Boehringer Ingelheim Investigational Site
Höchstädt, Germany
205.389.1726 Boehringer Ingelheim Investigational Site
Ingelheim, Germany
205.389.1873 Boehringer Ingelheim Investigational Site
Karlsruhe, Germany
205.389.1838 Boehringer Ingelheim Investigational Site
Kaufbeuren, Germany
205.389.1839 Boehringer Ingelheim Investigational Site
Koblenz, Germany
205.389.1881 Boehringer Ingelheim Investigational Site
Krefeld, Germany
205.389.1786 Boehringer Ingelheim Investigational Site
Krumpa, Germany
205.389.1704 Boehringer Ingelheim Investigational Site
Käbschütztal-Krögis, Germany
205.389.1974 Boehringer Ingelheim Investigational Site
Köln, Germany
205.389.1892 Boehringer Ingelheim Investigational Site
Köln, Germany
205.389.1813 Boehringer Ingelheim Investigational Site
Köthen, Germany
205.389.1902 Boehringer Ingelheim Investigational Site
Landsberg, Germany
205.389.1894 Boehringer Ingelheim Investigational Site
Leipzig, Germany
205.389.1908 Boehringer Ingelheim Investigational Site
Leipzig, Germany
205.389.1837 Boehringer Ingelheim Investigational Site
Leipzig, Germany
205.389.1841 Boehringer Ingelheim Investigational Site
Leipzig, Germany
205.389.1874 Boehringer Ingelheim Investigational Site
Leonberg, Germany
205.389.1955 Boehringer Ingelheim Investigational Site
Limburg, Germany
205.389.1904 Boehringer Ingelheim Investigational Site
Lorch, Germany
205.389.1877 Boehringer Ingelheim Investigational Site
Lübeck, Germany
205.389.1823 Boehringer Ingelheim Investigational Site
Lützen, Germany
205.389.1879 Boehringer Ingelheim Investigational Site
Magdeburg, Germany
205.389.1978 Boehringer Ingelheim Investigational Site
Mannheim, Germany
205.389.1840 Boehringer Ingelheim Investigational Site
Mannheim, Germany
205.389.1926 Boehringer Ingelheim Investigational Site
Marburg, Germany
205.389.1866 Boehringer Ingelheim Investigational Site
Marburg, Germany
205.389.1871 Boehringer Ingelheim Investigational Site
Marburg, Germany
205.389.1776 Boehringer Ingelheim Investigational Site
Marl, Germany
205.389.1779 Boehringer Ingelheim Investigational Site
Merrbusch, Germany
205.389.1799 Boehringer Ingelheim Investigational Site
München, Germany
205.389.1843 Boehringer Ingelheim Investigational Site
München, Germany
205.389.1815 Boehringer Ingelheim Investigational Site
München, Germany
205.389.1817 Boehringer Ingelheim Investigational Site
München, Germany
205.389.1952 Boehringer Ingelheim Investigational Site
Neubrandenburg, Germany
205.389.1948 Boehringer Ingelheim Investigational Site
Neuss, Germany
205.389.1958 Boehringer Ingelheim Investigational Site
Neuwied, Germany
205.389.1805 Boehringer Ingelheim Investigational Site
Neuötting, Germany
205.389.1830 Boehringer Ingelheim Investigational Site
Niesky, Germany
205.389.1711 Boehringer Ingelheim Investigational Site
Nussbach, Germany
205.389.1781 Boehringer Ingelheim Investigational Site
Oberdorla, Germany
205.389.1854 Boehringer Ingelheim Investigational Site
Paderborn, Germany
205.389.1753 Boehringer Ingelheim Investigational Site
Paderborn, Germany
205.389.1810 Boehringer Ingelheim Investigational Site
Paderborn, Germany
205.389.1756 Boehringer Ingelheim Investigational Site
Pirmasens, Germany
205.389.1899 Boehringer Ingelheim Investigational Site
Potsdam, Germany
205.389.1794 Boehringer Ingelheim Investigational Site
Potsdam, Germany
205.389.1842 Boehringer Ingelheim Investigational Site
Radebeul, Germany
205.389.1897 Boehringer Ingelheim Investigational Site
Rathenow, Germany
205.389.1950 Boehringer Ingelheim Investigational Site
Raubach, Germany
205.389.1783 Boehringer Ingelheim Investigational Site
Riesa, Germany
205.389.1826 Boehringer Ingelheim Investigational Site
Riesa, Germany
205.389.1742 Boehringer Ingelheim Investigational Site
Rostock, Germany
205.389.1816 Boehringer Ingelheim Investigational Site
Rüdersdorf, Germany
205.389.1883 Boehringer Ingelheim Investigational Site
Rüsselsheim, Germany
205.389.1878 Boehringer Ingelheim Investigational Site
Saarlouis, Germany
205.389.1833 Boehringer Ingelheim Investigational Site
Schmallenberg-Grafschaft, Germany
205.389.1973 Boehringer Ingelheim Investigational Site
Schmölln, Germany
205.389.1979 Boehringer Ingelheim Investigational Site
Schwetzingen, Germany
205.389.1856 Boehringer Ingelheim Investigational Site
Simmern, Germany
205.389.1918 Boehringer Ingelheim Investigational Site
Solingen, Germany
205.389.1822 Boehringer Ingelheim Investigational Site
Steinfurt, Germany
205.389.1728 Boehringer Ingelheim Investigational Site
Sulzbach, Germany
205.389.1717 Boehringer Ingelheim Investigational Site
Templin, Germany
205.389.1882 Boehringer Ingelheim Investigational Site
Treuenbrietzen, Germany
205.389.1745 Boehringer Ingelheim Investigational Site
Wallerfing, Germany
205.389.1800 Boehringer Ingelheim Investigational Site
Wardenburg, Germany
205.389.1885 Boehringer Ingelheim Investigational Site
Weißenhorn, Germany
205.389.1927 Boehringer Ingelheim Investigational Site
Westerstede, Germany
205.389.1825 Boehringer Ingelheim Investigational Site
Weyhe, Germany
205.389.1863 Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
205.389.1968 Boehringer Ingelheim Investigational Site
Wilhelmshaven, Germany
205.389.1807 Boehringer Ingelheim Investigational Site
Wilster, Germany
205.389.1754 Boehringer Ingelheim Investigational Site
Wolfsburg, Germany
205.389.1919 Boehringer Ingelheim Investigational Site
Wuppertal, Germany
205.389.1898 Boehringer Ingelheim Investigational Site
Zerbst, Germany
Hungary
205.389.2001 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2005 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2027 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2018 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2006 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2016 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2009 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.389.2007 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
205.389.2035 Boehringer Ingelheim Investigational Site
Deszk, Hungary
205.389.2015 Boehringer Ingelheim Investigational Site
Dunaújváros, Hungary
205.389.2011 Boehringer Ingelheim Investigational Site
Füzesabony, Hungary
205.389.2013 Boehringer Ingelheim Investigational Site
Gyor, Hungary
205.389.2028 Boehringer Ingelheim Investigational Site
Gyula, Hungary
205.389.2014 Boehringer Ingelheim Investigational Site
Jászberény, Hungary
205.389.2021 Boehringer Ingelheim Investigational Site
Kecskemét, Hungary
205.389.2025 Boehringer Ingelheim Investigational Site
Komárom, Hungary
205.389.2024 Boehringer Ingelheim Investigational Site
Mosdós, Hungary
205.389.2026 Boehringer Ingelheim Investigational Site
Mosonmagyaróvár, Hungary
205.389.2031 Boehringer Ingelheim Investigational Site
Nyíregyháza, Hungary
205.389.2002 Boehringer Ingelheim Investigational Site
Pécs, Hungary
205.389.2017 Boehringer Ingelheim Investigational Site
Ráckeve, Hungary
205.389.2003 Boehringer Ingelheim Investigational Site
Siófok, Hungary
205.389.2010 Boehringer Ingelheim Investigational Site
Szarvas, Hungary
205.389.2019 Boehringer Ingelheim Investigational Site
Szentendre, Hungary
205.389.2022 Boehringer Ingelheim Investigational Site
Százhalombatta, Hungary
205.389.2030 Boehringer Ingelheim Investigational Site
Tatabánya, Hungary
205.389.2029 Boehringer Ingelheim Investigational Site
Törökbálint, Hungary
205.389.2020 Boehringer Ingelheim Investigational Site
Veszprém, Hungary
205.389.2008 Boehringer Ingelheim Investigational Site
Érd, Hungary
Israel
205.389.2101 Boehringer Ingelheim Investigational Site
Afula, Israel
205.389.2110 Boehringer Ingelheim Investigational Site
Ashkelon, Israel
205.389.2106 Boehringer Ingelheim Investigational Site
Be'er-Sheva, Israel
205.389.2112 Boehringer Ingelheim Investigational Site
Hadera, Israel
205.389.2107 Boehringer Ingelheim Investigational Site
Haifa, Israel
205.389.2111 Boehringer Ingelheim Investigational Site
Haifa, Israel
205.389.2108 Boehringer Ingelheim Investigational Site
Holon, Israel
205.389.2104 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
205.389.2114 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
205.389.2116 Boehringer Ingelheim Investigational Site
Nahariya, Israel
205.389.2102 Boehringer Ingelheim Investigational Site
Petah Tiqwa, Israel
205.389.2105 Boehringer Ingelheim Investigational Site
Rehovot, Israel
205.389.2103 Boehringer Ingelheim Investigational Site
Tel Hashomer, Israel
205.389.2117 Boehringer Ingelheim Investigational Site
Zerifin, Israel
Italy
205.389.2211 Boehringer Ingelheim Investigational Site
Brescia, Italy
205.389.2206 Boehringer Ingelheim Investigational Site
Cagliari, Italy
205.389.2223 Boehringer Ingelheim Investigational Site
Catania, Italy
205.389.2209 Boehringer Ingelheim Investigational Site
Ferrara, Italy
205.389.2214 Boehringer Ingelheim Investigational Site
Genova, Italy
205.389.2215 Boehringer Ingelheim Investigational Site
Lecco, Italy
205.389.2226 Boehringer Ingelheim Investigational Site
Milano, Italy
205.389.2221 Boehringer Ingelheim Investigational Site
Milano, Italy
205.389.2224 Boehringer Ingelheim Investigational Site
Modena, Italy
205.389.2203 Boehringer Ingelheim Investigational Site
Montescano (PV), Italy
205.389.2230 Boehringer Ingelheim Investigational Site
Napoli, Italy
205.389.2201 Boehringer Ingelheim Investigational Site
Novara, Italy
205.389.2229 Boehringer Ingelheim Investigational Site
Pavia, Italy
205.389.2227 Boehringer Ingelheim Investigational Site
Pisa, Italy
205.389.2228 Boehringer Ingelheim Investigational Site
Roma, Italy
205.389.2205 Boehringer Ingelheim Investigational Site
Roma, Italy
205.389.2210 Boehringer Ingelheim Investigational Site
Sassari, Italy
205.389.2232 Boehringer Ingelheim Investigational Site
Treviso, Italy
Latvia
205.389.2315 Boehringer Ingelheim Investigational Site
Balvi, Latvia
205.389.2305 Boehringer Ingelheim Investigational Site
Daugavpils, Latvia
205.389.2313 Boehringer Ingelheim Investigational Site
Jelgava, Latvia
205.389.2311 Boehringer Ingelheim Investigational Site
Kraslava, Latvia
205.389.2312 Boehringer Ingelheim Investigational Site
Kuldiga, Latvia
205.389.2303 Boehringer Ingelheim Investigational Site
Riga, Latvia
205.389.2307 Boehringer Ingelheim Investigational Site
Riga, Latvia
205.389.2310 Boehringer Ingelheim Investigational Site
Riga, Latvia
205.389.2301 Boehringer Ingelheim Investigational Site
Riga, Latvia
205.389.2306 Boehringer Ingelheim Investigational Site
Talsi, Latvia
205.389.2314 Boehringer Ingelheim Investigational Site
Tukums, Latvia
205.389.2304 Boehringer Ingelheim Investigational Site
Valmiera, Latvia
205.389.2302 Boehringer Ingelheim Investigational Site
Ventspils, Latvia
Lithuania
205.389.2401 Boehringer Ingelheim Investigational Site
Alytus, Lithuania
205.389.2404 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.389.2403 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.389.2402 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.389.2406 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.389.2409 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.389.2407 Boehringer Ingelheim Investigational Site
Klaipeda, Lithuania
205.389.2411 Boehringer Ingelheim Investigational Site
Klaipeda, Lithuania
205.389.2408 Boehringer Ingelheim Investigational Site
Siauliai, Lithuania
205.389.2410 Boehringer Ingelheim Investigational Site
Utena, Lithuania
205.389.2412 Boehringer Ingelheim Investigational Site
Vilnius, Lithuania
205.389.2414 Boehringer Ingelheim Investigational Site
Vilnius, Lithuania
205.389.2405 Boehringer Ingelheim Investigational Site
Vilnius, Lithuania
205.389.2413 Boehringer Ingelheim Investigational Site
Vilnius, Lithuania
Netherlands
205.389.2504 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
205.389.2508 Boehringer Ingelheim Investigational Site
te Leiderdrop, Netherlands
205.389.2510 Boehringer Ingelheim Investigational Site
Velp, Netherlands
205.389.2511 Boehringer Ingelheim Investigational Site
Zoetermeer, Netherlands
Norway
205.389.2614 Boehringer Ingelheim Investigational Site
Alesund, Norway
205.389.2604 Boehringer Ingelheim Investigational Site
Bekkestua, Norway
205.389.2601 Boehringer Ingelheim Investigational Site
Elverum, Norway
205.389.2611 Boehringer Ingelheim Investigational Site
Follebu, Norway
205.389.2602 Boehringer Ingelheim Investigational Site
Hamar, Norway
205.389.2613 Boehringer Ingelheim Investigational Site
Harstad, Norway
205.389.2610 Boehringer Ingelheim Investigational Site
Harstad, Norway
205.389.2609 Boehringer Ingelheim Investigational Site
Hønefoss, Norway
205.389.2608 Boehringer Ingelheim Investigational Site
Lørenskog, Norway
205.389.2612 Boehringer Ingelheim Investigational Site
Oslo, Norway
205.389.2605 Boehringer Ingelheim Investigational Site
Oslo, Norway
205.389.2616 Boehringer Ingelheim Investigational Site
Stavanger, Norway
Poland
205.389.2762 Boehringer Ingelheim Investigational Site
Bialystok, Poland
205.389.2765 Boehringer Ingelheim Investigational Site
Bialystok, Poland
205.389.2744 Boehringer Ingelheim Investigational Site
Bialystok, Poland
205.389.2708 Boehringer Ingelheim Investigational Site
Bialystok, Poland
205.389.2778 Boehringer Ingelheim Investigational Site
Bielsko-Biala, Poland
205.389.2706 Boehringer Ingelheim Investigational Site
Bienkowka 410, Poland
205.389.2750 Boehringer Ingelheim Investigational Site
Brzesko, Poland
205.389.2758 Boehringer Ingelheim Investigational Site
Bydgoszcz, Poland
205.389.2773 Boehringer Ingelheim Investigational Site
Bystra, Poland
205.389.2800 Boehringer Ingelheim Investigational Site
Chodziez, Poland
205.389.2774 Boehringer Ingelheim Investigational Site
Czestochowa, Poland
205.389.2712 Boehringer Ingelheim Investigational Site
Czestochowa, Poland
205.389.2815 Boehringer Ingelheim Investigational Site
Dzialdowo, Poland
205.389.2787 Boehringer Ingelheim Investigational Site
Elblag, Poland
205.389.2764 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.389.2743 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.389.2802 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.389.2715 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.389.2723 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.389.2801 Boehringer Ingelheim Investigational Site
Gorzow Wlkp, Poland
205.389.2805 Boehringer Ingelheim Investigational Site
Ilawa, Poland
205.389.2791 Boehringer Ingelheim Investigational Site
Inowroclaw, Poland
205.389.2771 Boehringer Ingelheim Investigational Site
Katowice, Poland
205.389.2749 Boehringer Ingelheim Investigational Site
Katowice, Poland
205.389.2705 Boehringer Ingelheim Investigational Site
Katowice, Poland
205.389.2759 Boehringer Ingelheim Investigational Site
Koszalin, Poland
205.389.2798 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.389.2711 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.389.2753 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.389.2722 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.389.2747 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.389.2748 Boehringer Ingelheim Investigational Site
Kraków, Poland
205.389.2757 Boehringer Ingelheim Investigational Site
Kutno, Poland
205.389.2727 Boehringer Ingelheim Investigational Site
Leszno, Poland
205.389.2701 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2751 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2716 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2709 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2732 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2724 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2746 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.389.2804 Boehringer Ingelheim Investigational Site
Lomza, Poland
205.389.2776 Boehringer Ingelheim Investigational Site
Lublin, Poland
205.389.2817 Boehringer Ingelheim Investigational Site
Lublin, Poland
205.389.2741 Boehringer Ingelheim Investigational Site
Lublin, Poland
205.389.2760 Boehringer Ingelheim Investigational Site
Olawa, Poland
205.389.2756 Boehringer Ingelheim Investigational Site
Olsztyn, Poland
205.389.2816 Boehringer Ingelheim Investigational Site
Olsztyn, Poland
205.389.2702 Boehringer Ingelheim Investigational Site
Ostrow Wielkopolska, Poland
205.389.2726 Boehringer Ingelheim Investigational Site
Pabianice, Poland
205.389.2795 Boehringer Ingelheim Investigational Site
Plawno, Poland
205.389.2730 Boehringer Ingelheim Investigational Site
Plock, Poland
205.389.2719 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2769 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2703 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2737 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2813 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2766 Boehringer Ingelheim Investigational Site
Poznan, Poland
205.389.2763 Boehringer Ingelheim Investigational Site
Proszowice, Poland
205.389.2767 Boehringer Ingelheim Investigational Site
Pruszkow, Poland
205.389.2768 Boehringer Ingelheim Investigational Site
Radom, Poland
205.389.2792 Boehringer Ingelheim Investigational Site
Sandomierz, Poland
205.389.2781 Boehringer Ingelheim Investigational Site
Sieradz, Poland
205.389.2725 Boehringer Ingelheim Investigational Site
Skierniewice, Poland
205.389.2718 Boehringer Ingelheim Investigational Site
Szczecin, Poland
205.389.2772 Boehringer Ingelheim Investigational Site
Szczecin, Poland
205.389.2739 Boehringer Ingelheim Investigational Site
Szczecin, Poland
205.389.2782 Boehringer Ingelheim Investigational Site
Szczecin - Zdunowo, Poland
205.389.2777 Boehringer Ingelheim Investigational Site
Szczecin - Zdunowo, Poland
205.389.2738 Boehringer Ingelheim Investigational Site
Tarnow, Poland
205.389.2799 Boehringer Ingelheim Investigational Site
Tarnow, Poland
205.389.2810 Boehringer Ingelheim Investigational Site
Tczew, Poland
205.389.2775 Boehringer Ingelheim Investigational Site
Torun, Poland
205.389.2754 Boehringer Ingelheim Investigational Site
Tranow, Poland
205.389.2806 Boehringer Ingelheim Investigational Site
Turek, Poland
205.389.2803 Boehringer Ingelheim Investigational Site
Wabrzenzo, Poland
205.389.2728 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.389.2707 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.389.2714 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.389.2734 Boehringer Ingelheim Investigational Site
Warszawa, Poland
205.389.2818 Boehringer Ingelheim Investigational Site
Warszawa, Poland
205.389.2812 Boehringer Ingelheim Investigational Site
Warszawa, Poland
205.389.2710 Boehringer Ingelheim Investigational Site
Wodzislaw Slaski, Poland
205.389.2752 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2736 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2780 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2793 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2721 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2731 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2761 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.389.2783 Boehringer Ingelheim Investigational Site
Zabrze, Poland
205.389.2735 Boehringer Ingelheim Investigational Site
Zakopane, Poland
205.389.2770 Boehringer Ingelheim Investigational Site
Zgierz, Poland
Portugal
205.389.2912 Boehringer Ingelheim Investigational Site
Angra do Heroísmo, Portugal
205.389.2911 Boehringer Ingelheim Investigational Site
Barreiro, Portugal
205.389.2904 Boehringer Ingelheim Investigational Site
Faro, Portugal
205.389.2910 Boehringer Ingelheim Investigational Site
Figueira da Foz, Portugal
205.389.2907 Boehringer Ingelheim Investigational Site
Guarda, Portugal
205.389.2917 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
205.389.2914 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
205.389.2905 Boehringer Ingelheim Investigational Site
Santa Maria da Feira, Portugal
205.389.2909 Boehringer Ingelheim Investigational Site
Santiago do Cacem, Portugal
205.389.2903 Boehringer Ingelheim Investigational Site
Torres Vedras, Portugal
Romania
205.389.3023 Boehringer Ingelheim Investigational Site
Brasov, Romania
205.389.3018 Boehringer Ingelheim Investigational Site
Brasov, Romania
205.389.3009 Boehringer Ingelheim Investigational Site
Brasov, Romania
205.389.3025 Boehringer Ingelheim Investigational Site
Bucharest, Romania
205.389.3006 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3007 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3001 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3013 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3012 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3004 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3002 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
205.389.3016 Boehringer Ingelheim Investigational Site
Constanta, Romania
205.389.3019 Boehringer Ingelheim Investigational Site
Constanta, Romania
205.389.3015 Boehringer Ingelheim Investigational Site
Craiova, Romania
205.389.3008 Boehringer Ingelheim Investigational Site
Iasi, Romania
205.389.3014 Boehringer Ingelheim Investigational Site
Iasi, Romania
205.389.3022 Boehringer Ingelheim Investigational Site
Iasi, Romania
205.389.3024 Boehringer Ingelheim Investigational Site
Iasi, Romania
205.389.3005 Boehringer Ingelheim Investigational Site
Oradea, Romania
205.389.3017 Boehringer Ingelheim Investigational Site
Tg. Mures, Romania
205.389.3021 Boehringer Ingelheim Investigational Site
Timisoara, Romania
Russian Federation
205.389.3174 Boehringer Ingelheim Investigational Site
Arkhangelsk, Russian Federation
205.389.3131 Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
205.389.3113 Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
205.389.3105 Boehringer Ingelheim Investigational Site
Chelyabinsk, Russian Federation
205.389.3183 Boehringer Ingelheim Investigational Site
Chelyabinsk, Russian Federation
205.389.3184 Boehringer Ingelheim Investigational Site
Chelyabinsk, Russian Federation
205.389.3182 Boehringer Ingelheim Investigational Site
Chelyabinsk, Russian Federation
205.389.3166 Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
205.389.3116 Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
205.389.3138 Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
205.389.3148 Boehringer Ingelheim Investigational Site
Ekaterinburg, Russian Federation
205.389.3186 Boehringer Ingelheim Investigational Site
Gatchina (Leningradskaya oblast), Russian Federation
205.389.3193 Boehringer Ingelheim Investigational Site
Kaliningrad, Russian Federation
205.389.3104 Boehringer Ingelheim Investigational Site
Kazan, Russian Federation
205.389.3111 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
205.389.3120 Boehringer Ingelheim Investigational Site
Kirov, Russian Federation
205.389.3170 Boehringer Ingelheim Investigational Site
Krasnodar, Russian Federation
205.389.3132 Boehringer Ingelheim Investigational Site
Krasnoyarsk, Russian Federation
205.389.3108 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3103 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3107 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3106 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3143 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3130 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3127 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3128 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3125 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3136 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3134 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3139 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3140 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3109 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3149 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3151 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3156 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3157 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3164 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3196 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3167 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3168 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3171 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3163 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
205.389.3188 Boehringer Ingelheim Investigational Site
Murmansk, Russian Federation
205.389.3953 Boehringer Ingelheim Investigational Site
Nizhniy Novgorod, Russian Federation
205.389.3169 Boehringer Ingelheim Investigational Site
Nizhny Novgorod, Russian Federation
205.389.3175 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3141 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3129 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3114 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3112 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3153 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
205.389.3126 Boehringer Ingelheim Investigational Site
Orenburg, Russian Federation
205.389.3185 Boehringer Ingelheim Investigational Site
Perm, Russian Federation
205.389.3192 Boehringer Ingelheim Investigational Site
Petrozavodsk, Russian Federation
205.389.3179 Boehringer Ingelheim Investigational Site
Pskov, Russian Federation
205.389.3190 Boehringer Ingelheim Investigational Site
Pskov, Russian Federation
205.389.3199 Boehringer Ingelheim Investigational Site
Pyatigorsk,, Russian Federation
205.389.3159 Boehringer Ingelheim Investigational Site
Rostov-on-Don, Russian Federation
205.389.3197 Boehringer Ingelheim Investigational Site
Ryazan, Russian Federation
205.389.3198 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russian Federation
205.389.3951 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
205.389.3110 Boehringer Ingelheim Investigational Site
Saratov, Russian Federation
205.389.3191 Boehringer Ingelheim Investigational Site
St-Petersburg, Russian Federation
205.389.3122 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3137 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3121 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3176 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3177 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3178 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3145 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3180 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3181 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3146 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3123 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3119 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3160 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3135 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3161 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3189 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3950 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3195 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
205.389.3165 Boehringer Ingelheim Investigational Site
St.Peterburg, Russian Federation
205.389.3147 Boehringer Ingelheim Investigational Site
St.Petersburg, Russian Federation
205.389.3117 Boehringer Ingelheim Investigational Site
St.Petersburg, Russian Federation
205.389.3152 Boehringer Ingelheim Investigational Site
St.Petersburg, Russian Federation
205.389.3101 Boehringer Ingelheim Investigational Site
Tomsk, Russian Federation
205.389.3102 Boehringer Ingelheim Investigational Site
Tomsk, Russian Federation
205.389.3133 Boehringer Ingelheim Investigational Site
Tomsk, Russian Federation
205.389.3144 Boehringer Ingelheim Investigational Site
Tomsk, Russian Federation
205.389.3194 Boehringer Ingelheim Investigational Site
Velikiy Novgorod, Russian Federation
205.389.3118 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
205.389.3155 Boehringer Ingelheim Investigational Site
Yaroslavl, Russian Federation
Slovakia
205.389.3208 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
205.389.3204 Boehringer Ingelheim Investigational Site
Kosice, Slovakia
205.389.3209 Boehringer Ingelheim Investigational Site
Kosice, Slovakia
205.389.3205 Boehringer Ingelheim Investigational Site
Prievidza, Slovakia
205.389.3210 Boehringer Ingelheim Investigational Site
Revuca, Slovakia
205.389.3203 Boehringer Ingelheim Investigational Site
Spisska Nova Ves, Slovakia
205.389.3202 Boehringer Ingelheim Investigational Site
Trnava, Slovakia
205.389.3207 Boehringer Ingelheim Investigational Site
Vrable, Slovakia
Slovenia
205.389.3301 Boehringer Ingelheim Investigational Site
Golnik, Slovenia
205.389.3308 Boehringer Ingelheim Investigational Site
Grosuplje, Slovenia
205.389.3304 Boehringer Ingelheim Investigational Site
Jesenice, Slovenia
205.389.3302 Boehringer Ingelheim Investigational Site
Kamnik, Slovenia
205.389.3303 Boehringer Ingelheim Investigational Site
Ljubljana, Slovenia
205.389.3306 Boehringer Ingelheim Investigational Site
Topolsica, Slovenia
Spain
205.389.3410 Boehringer Ingelheim Investigational Site
Badajoz, Spain
205.389.3403 Boehringer Ingelheim Investigational Site
Badalona (Barcelona), Spain
205.389.3401 Boehringer Ingelheim Investigational Site
Barcelona, Spain
205.389.3428 Boehringer Ingelheim Investigational Site
Barcelona, Spain
205.389.3402 Boehringer Ingelheim Investigational Site
Barcelona, Spain
205.389.3430 Boehringer Ingelheim Investigational Site
Cartagena, Spain
205.389.3416 Boehringer Ingelheim Investigational Site
Cáceres, Spain
205.389.3425 Boehringer Ingelheim Investigational Site
Elche, Spain
205.389.3408 Boehringer Ingelheim Investigational Site
Las Palmas de Gran Canarias, Spain
205.389.3405 Boehringer Ingelheim Investigational Site
Lleida, Spain
205.389.3404 Boehringer Ingelheim Investigational Site
Madrid, Spain
205.389.3406 Boehringer Ingelheim Investigational Site
Madrid, Spain
205.389.3414 Boehringer Ingelheim Investigational Site
Málaga, Spain
205.389.3431 Boehringer Ingelheim Investigational Site
Pontevedra, Spain
205.389.3419 Boehringer Ingelheim Investigational Site
Requena, Spain
205.389.3427 Boehringer Ingelheim Investigational Site
Reus, Spain
205.389.3422 Boehringer Ingelheim Investigational Site
Sagunto, Spain
205.389.3420 Boehringer Ingelheim Investigational Site
San Juan, Spain
205.389.3415 Boehringer Ingelheim Investigational Site
Santander, Spain
205.389.3421 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
205.389.3407 Boehringer Ingelheim Investigational Site
Terrasa (Barcelona), Spain
205.389.3413 Boehringer Ingelheim Investigational Site
Valencia, Spain
205.389.3426 Boehringer Ingelheim Investigational Site
Valencia, Spain
205.389.3417 Boehringer Ingelheim Investigational Site
Valladolid, Spain
Turkey
205.389.3821 Boehringer Ingelheim Investigational Site
Adana, Turkey
205.389.3808 Boehringer Ingelheim Investigational Site
Ankara, Turkey
205.389.3810 Boehringer Ingelheim Investigational Site
Ankara, Turkey
205.389.3817 Boehringer Ingelheim Investigational Site
Bursa, Turkey
205.389.3819 Boehringer Ingelheim Investigational Site
Erzurum, Turkey
205.389.3812 Boehringer Ingelheim Investigational Site
Istanbul, Turkey
205.389.3827 Boehringer Ingelheim Investigational Site
Izmir, Turkey
205.389.3813 Boehringer Ingelheim Investigational Site
Izmit, Turkey
205.389.3820 Boehringer Ingelheim Investigational Site
Kahramanmaras, Turkey
205.389.3825 Boehringer Ingelheim Investigational Site
Malatya, Turkey
205.389.3809 Boehringer Ingelheim Investigational Site
Sihhiye Ankara, Turkey
205.389.3807 Boehringer Ingelheim Investigational Site
Yenisehir-IZMIR, Turkey
Ukraine
205.389.3521 Boehringer Ingelheim Investigational Site
AR Crimea, Ukraine
205.389.3516 Boehringer Ingelheim Investigational Site
Cherkassy, Ukraine
205.389.3549 Boehringer Ingelheim Investigational Site
Chernivtsi, Ukraine
205.389.3523 Boehringer Ingelheim Investigational Site
Dnipropetrovsk, Ukraine
205.389.3511 Boehringer Ingelheim Investigational Site
Dnipropetrovsk, Ukraine
205.389.3509 Boehringer Ingelheim Investigational Site
Dnipropetrovsk, Ukraine
205.389.3510 Boehringer Ingelheim Investigational Site
Dnipropetrovsk, Ukraine
205.389.3514 Boehringer Ingelheim Investigational Site
Donetsk, Ukraine
205.389.3524 Boehringer Ingelheim Investigational Site
Donetsk, Ukraine
205.389.3533 Boehringer Ingelheim Investigational Site
Ivano-Frankivsk, Ukraine
205.389.3532 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3543 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3555 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3522 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3539 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3520 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3506 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3507 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3508 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3541 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
205.389.3502 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3503 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3501 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3552 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3553 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3550 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
205.389.3534 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3551 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3528 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3538 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3525 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3526 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3535 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3536 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3504 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
205.389.3545 Boehringer Ingelheim Investigational Site
Lugansk, Ukraine
205.389.3512 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
205.389.3540 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
205.389.3530 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
205.389.3554 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
205.389.3556 Boehringer Ingelheim Investigational Site
m.Donetsk, Ukraine
205.389.3513 Boehringer Ingelheim Investigational Site
m.Odesa, Ukraine
205.389.3542 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
205.389.3519 Boehringer Ingelheim Investigational Site
Odesa, Ukraine
205.389.3527 Boehringer Ingelheim Investigational Site
Odessa, Ukraine
205.389.3531 Boehringer Ingelheim Investigational Site
Poltava, Ukraine
205.389.3517 Boehringer Ingelheim Investigational Site
Simferopil, Ukraine
205.389.3518 Boehringer Ingelheim Investigational Site
Ternopil, Ukraine
205.389.3529 Boehringer Ingelheim Investigational Site
Vinnitsa, Ukraine
205.389.3515 Boehringer Ingelheim Investigational Site
Zaporizhzhya, Ukraine
205.389.3548 Boehringer Ingelheim Investigational Site
Zaporizhzhya, Ukraine
205.389.3547 Boehringer Ingelheim Investigational Site
Zaporizhzhya, Ukraine
United Kingdom
205.389.3601 Boehringer Ingelheim Investigational Site
Bath, United Kingdom
205.389.3630 Boehringer Ingelheim Investigational Site
Bexhill on Sea, United Kingdom
205.389.3636 Boehringer Ingelheim Investigational Site
Bexhill-on-Sea, United Kingdom
205.389.3608 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
205.389.3605 Boehringer Ingelheim Investigational Site
Blackburn, United Kingdom
205.389.3609 Boehringer Ingelheim Investigational Site
Bolton, United Kingdom
205.389.3640 Boehringer Ingelheim Investigational Site
Burbage, United Kingdom
205.389.3643 Boehringer Ingelheim Investigational Site
Chesterfield, United Kingdom
205.389.3627 Boehringer Ingelheim Investigational Site
Corsham, United Kingdom
205.389.3606 Boehringer Ingelheim Investigational Site
Coventry, United Kingdom
205.389.3633 Boehringer Ingelheim Investigational Site
Coventry, United Kingdom
205.389.3639 Boehringer Ingelheim Investigational Site
Frome, United Kingdom
205.389.3602 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
205.389.3632 Boehringer Ingelheim Investigational Site
Irvine, United Kingdom
205.389.3623 Boehringer Ingelheim Investigational Site
London, United Kingdom
205.389.3638 Boehringer Ingelheim Investigational Site
Middlesex, United Kingdom
205.389.3616 Boehringer Ingelheim Investigational Site
Newcastle upon Tyne, United Kingdom
205.389.3618 Boehringer Ingelheim Investigational Site
Paisley, United Kingdom
205.389.3622 Boehringer Ingelheim Investigational Site
Radstock, United Kingdom
205.389.3626 Boehringer Ingelheim Investigational Site
Randalstown, United Kingdom
205.389.3604 Boehringer Ingelheim Investigational Site
Soham, United Kingdom
205.389.3613 Boehringer Ingelheim Investigational Site
St Just, Penzance, United Kingdom
205.389.3624 Boehringer Ingelheim Investigational Site
Sunderland, United Kingdom
205.389.3635 Boehringer Ingelheim Investigational Site
Wansford, Peterborough, United Kingdom
205.389.3631 Boehringer Ingelheim Investigational Site
Windsor, United Kingdom
205.389.3612 Boehringer Ingelheim Investigational Site
Wrexham, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Pfizer
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00563381     History of Changes
Other Study ID Numbers: 205.389, EUDRACT2007-001840-33
Study First Received: November 22, 2007
Results First Received: March 29, 2011
Last Updated: November 27, 2013
Health Authority: Austria: AGES, Oesterreichische Agentur für Gesundheit und Ernaehrungssicherheit
Belgium: AFMPS - Agence Fédérale des Médicaments et des Produits des Santé
Bulgaria: Bulgarian Drug Agency
Czech Republic: State Institute for Drug Control
Denmark: The Danish Medicines Agency
Finland: Finnish Medicines Agency
France: AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé)
Germany: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
Great Britain: Medicines and Heathcare Products Regulatory Agency
Hungary: ORSZÁGOS GYÓGYSZERÉSZETI INTÉZET
Israel: not applicable
Italy: COMITATO ETICO DELLA PROVINCIA DI FERRARA
Latvia: State Agency of Medicines
Lithuania: Lithuanian Bioethics Committee
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Norway: Norwegian Medicines Agency
Poland: Agency for Registration of Medicinal Products, Medical Devices & Biocides
Portugal: INFARMED - Instituto Nacional da Farmácia e do Medicamento
Romania: National Medicines Agency
Russia: Federal Service On Surveillance In Healthcare And Social Development Of Russian Federation
Slovakia: State Institute for Drug Control
Slovenia: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Turkey: Ministery Of Health / Central Ethics Committee
Ukraine: The State Pharmacological Center of Ministry of Health of Ukraine
United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Lung Diseases, Obstructive
Bromides
Salmeterol
Tiotropium
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents

ClinicalTrials.gov processed this record on August 20, 2014